Skip to content

Effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)

Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180114038350N3
Enrollment
80
Registered
2020-05-01
Start date
2020-05-04
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Covid 19. Covid 19

Interventions

Intervention 1: Intervention group: Oral Deferiprone is added to drugs used to treat Covid 19 (approved by the National Committee). Intervention 2: Control group: Patients receive only the drugs used

Sponsors

Sanandaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Covid 19 patients without needing ventilator Age between 18 to 80

Exclusion criteria

Exclusion criteria: Patients with anemia Patients with gastroenteritis Patients who had history of liver diseases Patients who had history of renal diseases

Design outcomes

Primary

MeasureTime frame
Improvement in disease symptoms (Fever and breathing). Timepoint: This primary outcome is measured for patients before and during 5 days after treatment initiation. Method of measurement: Fever is calculated using mercury thermometers and respiration is calculated using the number of breaths per minute.

Secondary

MeasureTime frame
Duration of hospital stay. Timepoint: Based on the number of days a person is hospitalized. Method of measurement: Medical records.;Improvement in SPO2 to FiO2 ratio. Timepoint: Percent of SPO2. Method of measurement: Based on Oximeter pulse.;Death. Timepoint: Number of death in each group. Method of measurement: Medical Records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhaled Rahmani

Sanandaj University of Medical Sciences

khaledrahmani111@yahoo.com+98 87 3366 4673

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026